Journals / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 1

How should we describe, diagnose and observe the Barrett's esophagus?

Pages
26–30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the presence of BE with high-grade dysplasia (HGD), the patients should be referred to specialized centers for treatment within 3 months at the latest

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Barrett's esophagus (BE) is one of the major complications of gastroesophageal reflux disease (GERD) commonly encountered in gastroenterology clinics.
📊
Key Findings & Data:Undertaking biopsies with white-light endoscopy from each of the 4 quadrants at 2-cm intervals is the standard method for the diagnosis of BE.
💡
Conclusion & Impact:In the presence of BE with high-grade dysplasia (HGD), the patients should be referred to specialized centers for treatment within 3 months at the latest
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Barrett's esophagus (BE) is one of the major complications of gastroesophageal reflux disease (GERD) commonly encountered in gastroenterology clinics. A consensus has not been achieved yet with respect to the definition of BE in published guidelines. It is advised to use the Prague classification and not to use the definition of short and long segments for the endoscopic standardization of BE. Undertaking biopsies with white-light endoscopy from each of the 4 quadrants at 2-cm intervals is the standard method for the diagnosis of BE. Because of the ability to perform targeted biopsies, the available data indicate that advanced endoscopic techniques may reduce the number of biopsies needed for diagnoses. In the presence of severe esophagitis along with BE, the biopsies should be taken after 8 weeks of PPI therapy. The evidence values of the suggestions about the surveillance requirements and surveillance frequencies are low because the available data mostly rely on retrospective studies. We suggest that all the patients with BE should be referred to specialized centers for surveillance in Turkey. Considering the additional risk factors of the patient, endoscopy surveillance intervals of the patients with BE without dysplasia should be in a range of 3-5 years and annual surveillance should be made in BE with low-grade dysplasia. In the presence of BE with high-grade dysplasia (HGD), the patients should be referred to specialized centers for treatment within 3 months at the latest

🔖

Cite This Article

AKIN, H., AYDIN, Y. (2017). How should we describe, diagnose and observe the Barrett's esophagus?. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 1, 26–30. https://ajindex.com/articles/410729

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014
  2. [CrossRef] 2. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ
  3. American Gastroenterological Association. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011
  4. e18-52. 3. Kelty CJ, Gough MD, Van Wyk Q, Stephenson TJ, Ackroyd R. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007
  5. [CrossRef] 4. Takubo K, Aida J, Naomoto Y, et al. Cardiac rather than intestinaltype background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 2009
  6. [CrossRef] 5. Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 2009
  7. [CrossRef] 6. Hahn HP, Blount PL, Ayub K, et al. Intestinal differentiation in metaplastic, nongoblet columar epithelium in the esophagus. Am J Surg Pathol 2009
  8. [CrossRef] 7. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large populationbased study. J Natl Cancer Inst 2011
  9. [CrossRef] 8. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011
  10. [CrossRef] 9. Bansal A, McGregor DH, Anand O, et al. Presence or absence of intestinal metaplasia but not its urden is associated with prevalent high-grade dysplasia and cancer in Barrett's esophagus. Dis Esophagus 2014
  11. [CrossRef] 10. Kim JB, Shin SR, Shin WG, et al. Prevalence of minimal change lesions in patients with non-erosive reflux disease: a case-control study. Digestion 2012
  12. [CrossRef] 11. Dickman R, Levi Z, Vilkin A, Zvidi I, Niv Y. Predictors of specialized intestinal metaplasia in patients with an incidental irregular Z line. Eur J Gastroenterol Hepatol 2010
  13. [CrossRef] 12. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011
  14. [CrossRef] 13. Sharma P, Dent J, Armstro